Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS

Ad hoc announcement pursuant to Art. 53 LR

• The approximately 20 million US lives covered by CVS will now have easier and more affordable access to QUVIVIQ

Allschwil, Switzerland & Radnor, PA, United States – July 10, 2023
Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals US Inc. today announced that, effective immediately, CVS is covering QUVIVIQ (daridorexant) CIV on the Performance Drug List (PDL). Approximately 20 million people are enrolled in this CVS plan, providing increased access to QUVIVIQ for the millions of adults who can benefit from this latest prescription insomnia therapy. QUVIVIQ is now covered by two of the largest insurance plans in the US, Express Scripts and CVS, and several associated regional plans, as well as TRICARE, the healthcare program for active and retired US military personnel and their families.

QUVIVIQ was approved in January 2022 for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.¹ It is a dual orexin receptor antagonist (DORA), which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain. Since availability of the product in May 2022, QUVIVIQ has quickly gained traction with patients and physicians, and more than 180,000 prescriptions have been dispensed to date.

Sleep is overwhelmingly seen as the third pillar of health, alongside diet and exercise. Poor quality or insufficient sleep can affect many aspects of the daily lives of people with trouble sleeping including the ability to concentrate, mood and energy levels.²

Patty Torr, Idorsia US President and General Manager, commented:
“Millions of Americans with insomnia are not getting enough nightly sleep. With CVS adding QUVIVIQ to their national formulary, insomnia patients will now have affordable access to this latest prescription medication, helping them get the sleep they need.”

In the long-term, insomnia is associated with numerous serious health conditions, such as psychiatric disorders, cardiovascular disease, type 2 diabetes, substance abuse and dementia.^3,4,5

For more information about QUVIVIQ, see the Full Prescribing Information and Medication Guide

Important Safety Information

QUVIVIQ is a prescription medicine for adults who have trouble falling asleep or staying asleep (insomnia).

Do not take QUVIVIQ if you fall asleep often at unexpected times (narcolepsy).